Description
EO14042-PURPOSE OF MODIFICATION: INCORPORATE FAR CLAUSE 52.223-99 & VHA SUPPLEMENTAL CONTRACT REQUIREMENTS FOR ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS. | MOD TO DECREASE OY 3
Base award description: RADIOPHARMACEUTICALS
Modification chain · 11 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2018-07-01+$139,445= $139,445
- Mod P000012018-09-27+$0= $139,445
- Mod P000022018-10-01+$1,000,000= $1,139,445
- Mod P000032019-10-01+$1,000,000= $2,139,445
- Mod P000042020-10-01+$1,000,000= $3,139,445
- Mod P000052020-12-16-$433,943= $2,705,502
- Mod P000072021-04-19-$606,463= $2,099,039
- Mod P000062021-04-23-$3,006= $2,096,033
- Mod P000082021-10-01+$989,692= $3,085,726
- Mod P000102022-12-21-$520,189= $2,565,537
- Mod P000112023-06-02-$612,681= $1,952,856
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2018-07-01 | +$139,445 | $139,445 | RADIOPHARMACEUTICALS |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2018-09-27 | +$0 | $139,445 | RADIOPHARMACEUTICALS |
| Mod P00002· EXERCISE AN OPTION | 2018-10-01 | +$1,000,000 | $1,139,445 | RADIOPHARMACEUTICALS |
| Mod P00003· EXERCISE AN OPTION | 2019-10-01 | +$1,000,000 | $2,139,445 | RADIOPHARMACEUTICALS |
| Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-10-01 | +$1,000,000 | $3,139,445 | RADIOPHARMACEUTICALS |
| Mod P00005· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-12-16 | −$433,943 | $2,705,502 | PO 688-C90076 | MOD P00005 | DEOBLIGATE EXCESS FUNDS FROM OPTION YEAR ONE |
| Mod P00007· FUNDING ONLY ACTION | 2021-04-19 | −$606,463 | $2,099,039 | PO 688-C00031 | MOD P00007 | DEOBLIGATE EXCESS FUNDS FROM OPTION YEAR TWO |
| Mod P00006· FUNDING ONLY ACTION | 2021-04-23 | −$3,006 | $2,096,033 | REMOVE VIZAMYL MOD |
| Mod P00008· EXERCISE AN OPTION | 2021-10-01 | +$989,692 | $3,085,726 | RADIOPHARMACEUTICALS, EXERCISING OPTION YEAR 4 |
| Mod P00010· FUNDING ONLY ACTION | 2022-12-21 | −$520,189 | $2,565,537 | EO14042 - PURPOSE OF MODIFICATION: TO INCORPORATE FAR CLAUSE 52.223-99 AND VHA SUPPLEMENTAL CONTRACT REQUIREM… |
| Mod P00011· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2023-06-02 | −$612,681 | $1,952,856 | EO14042-PURPOSE OF MODIFICATION: INCORPORATE FAR CLAUSE 52.223-99 & VHA SUPPLEMENTAL CONTRACT REQUIREMENTS FOR… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI CWN9UGL3NCL9)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24226N0711 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 3650 · CHEMICAL AND PHARMACEUTICAL PRODUCTS MANUFACTURING MACHINERY | $100,008 | FY2026 |
| 36C24126P0328 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $999,797 | FY2026 |
| 36C25726N0407 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6505 · DRUGS AND BIOLOGICALS | $1,400,000 | FY2026 |
| 36C25526N0361 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS | $228,679 | FY2026 |
| 36C24426N0938 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $650,641 | FY2026 |
| 36C24426D0097 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
Other recipients under 6505 from 245-NETWORK CONTRACT OFFICE 5 (36C245) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24526N0840 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $19,139 | FY2026 |
| 36C24526N0839 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $38,360 | FY2026 |
| 36C24526N0837 | QOL MEDICAL LLC | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $16,945 | FY2026 |
| 36C24526N0835 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $34,605 | FY2026 |
| 36C24526N0834 | GALDERMA LABORATORIES, L.P. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $16,960 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24518C0161_3600_-NONE-_-NONE- · retrieved 2026-09-26.